coIMMUNE Revenue and Competitors

Location

N/A

Total Funding

Research

Industry

Estimated Revenue & Valuation

  • coIMMUNE's estimated annual revenue is currently $3.6M per year.(i)
  • coIMMUNE's estimated revenue per employee is $77,520

Employee Data

  • coIMMUNE has 46 Employees.(i)
  • coIMMUNE grew their employee count by -2% last year.

coIMMUNE's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Director Quality AssuranceReveal Email/Phone
3
Director Quality ControlReveal Email/Phone
4
Chief Financial OfficerReveal Email/Phone
5
Process Development Senior ManagerReveal Email/Phone
6
Human Resources ManagerReveal Email/Phone
7
Regulatory Affairs ManagerReveal Email/Phone
8
Facility EngineerReveal Email/Phone
9
Materials Control Associate IIIReveal Email/Phone
10
Quality Assurance SpecialistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.4M42-2%N/AN/A
#2
$929.1M65064%N/AN/A
#3
$19.9M1771%N/AN/A
#4
$5.4M639%N/AN/A
#5
$0.9M15-40%N/AN/A
#6
$18.5M16911%$1.8MN/A
#7
$3.1M389%N/AN/A
#8
$16.3M1457%N/AN/A
#9
$10.9M10710%N/AN/A
#10
$4.9M53-2%N/AN/A
Add Company

What Is coIMMUNE?

CoImmune Inc. is a US company based in Durham North Carolina that was founded in 2019 based on its expertise in the development and manufacture of cell-based therapeutics to treat unmet medical needs including cancer, autoimmune and inflammatory diseases.

keywords:N/A

N/A

Total Funding

46

Number of Employees

$3.6M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

coIMMUNE News

2020-11-10 - CoImmune Closes $45 Million Series A Financing

DURHAM, N.C., Nov. 10, 2020 (GLOBE NEWSWIRE) -- CoImmune, Inc., an immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the closing of a $45M Series A financing. CoImmune will use the proceeds from the ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.1M46-19%$2.8M
#2
$9.9M46-10%N/A
#3
$9.9M467%N/A
#4
$7.1M4615%N/A
#5
$8.1M4610%N/A